---
layout: default
title: Ipilimumab
description: "Ipilimumab çš„è€è—¥æ–°ç”¨æ½›åŠ›åˆ†æã€‚æ¨¡å‹é æ¸¬ç­‰ç´š L5ï¼ŒåŒ…å« 2 å€‹é æ¸¬é©æ‡‰ç—‡ã€‚æŸ¥çœ‹ AI é æ¸¬èˆ‡è‡¨åºŠè­‰æ“šå®Œæ•´å ±å‘Šã€‚"
parent: åƒ…æ¨¡å‹é æ¸¬ (L5)
nav_order: 91
evidence_level: L1
indication_count: 2
---

# Ipilimumab

<p style="font-size: 1.25rem; color: #666; margin-bottom: 1.5rem;">
è­‰æ“šç­‰ç´š: <strong>L5</strong> | é æ¸¬é©æ‡‰ç—‡: <strong>2</strong> å€‹
</p>

---

<div id="pharmacist">

## è—¥å¸«è©•ä¼°å ±å‘Š

</div>

# Ipilimumab (æ˜“ä¹³è«å–®æŠ—) - è—¥å¸«è©•ä¼°å ±å‘Š

## ä¸€å¥è©±ç¸½çµ

<p class="key-answer" data-question="Ipilimumab å¯ä»¥ç”¨æ–¼æ²»ç™‚ä»€éº¼æ–°é©æ‡‰ç—‡ï¼Ÿ">
æ˜“ä¹³è«å–®æŠ—æ˜¯ä¸€ç¨®æŠ— CTLA-4 å…ç–«æª¢æŸ¥é»æŠ‘åˆ¶åŠ‘ï¼ŒTxGNN é æ¸¬å…¶å°éçš®è†šé»‘è‰²ç´ ç˜¤æœ‰ç™‚æ•ˆï¼Œé€™é …é æ¸¬ç²å¾—å¤§é‡è‡¨åºŠè©¦é©—æ”¯æŒï¼Œå±•ç¾äº†æ¥µé«˜çš„è½‰è­¯åƒ¹å€¼ã€‚
</p>

## å¿«é€Ÿç¸½è¦½

| é …ç›® | å…§å®¹ |
|------|------|
| è—¥ç‰©å­¸å | Ipilimumab |
| å°ç£å•†å“å | ç›Šä¼æ³¨å°„åŠ‘ 5 æ¯«å…‹/æ¯«å‡ (YERVOY) |
| DrugBank ID | DB06186 |
| åŸæ ¸å‡†é©æ‡‰ç—‡ | ç„¡æ³•åˆ‡é™¤æˆ–è½‰ç§»æ€§é»‘è‰²ç´ ç˜¤ã€è…ç´°èƒç™Œã€NSCLCã€è‚ç´°èƒç™Œã€å¤§è…¸ç›´è…¸ç™Œã€é£Ÿé“ç™Œç­‰ï¼ˆå¤šèˆ‡ nivolumab ä½µç”¨ï¼‰ |
| é æ¸¬æ–°é©æ‡‰ç—‡ | metastatic melanomaã€choroideremia |
| æœ€é«˜è­‰æ“šç­‰ç´š | L1/L2 (å¤šé … RCT ç ”ç©¶) |
| å°ç£ä¸Šå¸‚ç‹€æ…‹ | æœ‰æ•ˆè¨±å¯è­‰ |





## é æ¸¬é©æ‡‰ç—‡è©³ç´°åˆ†æ

<details class="indication-section" open>
<summary>
<span class="indication-name">1. choroideremia</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.06%</span> <span class="primary-badge">ä¸»è¦åˆ†æ</span>
</summary>
<div class="indication-content">

<h3>ç‚ºä»€éº¼é€™å€‹é æ¸¬åˆç†ï¼Ÿ</h3>

<p>Ipilimumab é€éé˜»æ–· CTLA-4 ä¾†å¢å¼· T ç´°èƒæ´»åŒ–ï¼Œè§£é™¤å…ç–«ç³»çµ±å°è…«ç˜¤çš„æŠ‘åˆ¶ï¼š</p>

<ol>
<li><strong>éçš®è†šé»‘è‰²ç´ ç˜¤</strong> (TxGNN Score: 0.990, Rank: 16733)ï¼š</li>
</ol>
<ul>
<li>åŒ…æ‹¬é»è†œé»‘è‰²ç´ ç˜¤ã€çœ¼éƒ¨é»‘è‰²ç´ ç˜¤ï¼ˆè‘¡è„è†œé»‘è‰²ç´ ç˜¤ï¼‰ç­‰</li>
<li>é€™äº›äºå‹è¼ƒçš®è†šé»‘è‰²ç´ ç˜¤å°‘è¦‹ï¼Œä½†å…·æœ‰ç›¸ä¼¼çš„å…ç–«åŸæ€§</li>
<li>Ipilimumabï¼ˆç‰¹åˆ¥æ˜¯èˆ‡ nivolumab ä½µç”¨ï¼‰å·²åœ¨é€™äº›äºå‹ä¸­é¡¯ç¤ºç™‚æ•ˆ</li>

</ul>
<ol>
<li><strong>è„ˆçµ¡è†œç„¡è™¹è†œç—‡ (Choroideremia)</strong> (TxGNN Score: 0.991, Rank: 16090)ï¼š</li>
</ol>
<ul>
<li>é€™æ˜¯ä¸€ç¨®éºå‚³æ€§è¦–ç¶²è†œé€€åŒ–ç–¾ç—…ï¼Œéè…«ç˜¤æ€§</li>
<li>æ­¤é æ¸¬çš„æ©Ÿè½‰é—œè¯ä¸æ˜ï¼Œå¯èƒ½ç‚ºå½é™½æ€§</li>
</ul>

<h3>è‡¨åºŠè©¦é©—</h3>

<p>ç›®å‰ç„¡é‡å°æ­¤ç‰¹å®šé©æ‡‰ç—‡çš„è‡¨åºŠè©¦é©—ç™»è¨˜ã€‚</p>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">2. non-cutaneous melanoma</span>
<span class="evidence-badge evidence-L1">L1</span>
<span class="prediction-score">99.02%</span>
</summary>
<div class="indication-content">

<h3>è‡¨åºŠè©¦é©—ï¼ˆ50 é …ï¼‰</h3>

<table>
<thead>
<tr><th>è©¦é©—ç·¨è™Ÿ</th><th>éšæ®µ</th><th>ç‹€æ…‹</th><th>äººæ•¸</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://clinicaltrials.gov/study/NCT05302921" target="_blank">NCT05302921</a></td><td>PHASE2</td><td>COMPLETED</td><td>5</td><td>Phase II Study Investigating the Efficacy of Neoadjuvant Dual Checkpoint Inhibit...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01827111" target="_blank">NCT01827111</a></td><td>PHASE2</td><td>COMPLETED</td><td>21</td><td>Phase II Study of Abraxane Plus Ipilimumab in Patients With Metastatic Melanoma</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01621490" target="_blank">NCT01621490</a></td><td>PHASE1</td><td>COMPLETED</td><td>170</td><td>An Exploratory Study of the Biologic Effects of Nivolumab and Ipilimumab Monothe...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT04074967" target="_blank">NCT04074967</a></td><td>PHASE1, PHASE2</td><td>ACTIVE_NOT_RECRUITING</td><td>70</td><td>A Phase Ib/II Study of ARRY-614 Plus Either Nivolumab or Nivolumab+Ipilimumab in...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01940809" target="_blank">NCT01940809</a></td><td>PHASE1</td><td>TERMINATED</td><td>15</td><td>A Sequential Safety and Biomarker Study of BRAF-MEK Inhibition on the Immune Res...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT02659540" target="_blank">NCT02659540</a></td><td>PHASE1</td><td>COMPLETED</td><td>20</td><td>A Pilot (Phase 1) Study to Evaluate the Safety and Efficacy of Combination Check...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT04107168" target="_blank">NCT04107168</a></td><td>N/A</td><td>UNKNOWN</td><td>1800</td><td>An Observational Study to Evaluate the Microbiome as a Biomarker of Efficacy and...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT02992912" target="_blank">NCT02992912</a></td><td>PHASE2</td><td>ACTIVE_NOT_RECRUITING</td><td>138</td><td>A Phase II Study to Assess the Efficacy of the Anti-PD-L1 Antibody Atezolizumab ...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01840007" target="_blank">NCT01840007</a></td><td>PHASE2</td><td>COMPLETED</td><td>20</td><td>Pilot Study Evaluating the Efficacy and Safety of Metformin in Melanoma</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT05584670" target="_blank">NCT05584670</a></td><td>PHASE1, PHASE2</td><td>RECRUITING</td><td>542</td><td>A Phase 1/2, Open Label, First-in-human, Dose Escalation and Expansion Study for...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT04418167" target="_blank">NCT04418167</a></td><td>PHASE1</td><td>SUSPENDED</td><td>71</td><td>A Phase 1 Study of ERK1/2 Inhibitor JSI-1187 Administered as Monotherapy and in ...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT03999749" target="_blank">NCT03999749</a></td><td>PHASE2</td><td>ACTIVE_NOT_RECRUITING</td><td>71</td><td>A Phase II Study of the Interleukin-6 Receptor Inhibitor Tocilizumab in Combinat...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT06880198" target="_blank">NCT06880198</a></td><td>NA</td><td>RECRUITING</td><td>20</td><td>An Interventional, Not Pharmacological Study to Evaluate ImpactÂ® as Support to A...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01838200" target="_blank">NCT01838200</a></td><td>PHASE1</td><td>TERMINATED</td><td>5</td><td>A Phase I Study of Intralesional Bacillus Calmette-Guerin (BCG) and Followed by ...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT02073123" target="_blank">NCT02073123</a></td><td>PHASE1, PHASE2</td><td>COMPLETED</td><td>132</td><td>A Phase 1/2 Study of the Concomitant Administration of Indoximod Plus Immune Che...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT03509584" target="_blank">NCT03509584</a></td><td>PHASE1</td><td>TERMINATED</td><td>6</td><td>Phase I Multicenter Trial Combining Nivolumab, Alone or With Ipilimumab, Plus Hy...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT02224768" target="_blank">NCT02224768</a></td><td>N/A</td><td>COMPLETED</td><td>158</td><td>YERVOY Risk Minimisation Tool Evaluation Survey</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01608594" target="_blank">NCT01608594</a></td><td>PHASE1</td><td>COMPLETED</td><td>30</td><td>Neoadjuvant Combination Biotherapy With Ipilimumab (3 mg/kg or 10 mg/kg) and Hig...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT03618641" target="_blank">NCT03618641</a></td><td>PHASE2</td><td>COMPLETED</td><td>34</td><td>Neoadjuvant Phase II Study of TLR9 Agonist CMP-001 in Combination With Nivolumab...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT03220009" target="_blank">NCT03220009</a></td><td>PHASE2</td><td>WITHDRAWN</td><td>0</td><td>A Randomized Phase II Trial of Adjuvant Nivolumab or Expectant Observation Follo...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT04988841" target="_blank">NCT04988841</a></td><td>PHASE2</td><td>COMPLETED</td><td>70</td><td>Prospective randomIzed Clinical Trial Assessing the Tolerance and Clinical Benef...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT06581406" target="_blank">NCT06581406</a></td><td>PHASE2, PHASE3</td><td>RECRUITING</td><td>280</td><td>A Randomized, Phase 2/3, Open-Label Study to Investigate the Efficacy and Safety...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT04605146" target="_blank">NCT04605146</a></td><td>NA</td><td>RECRUITING</td><td>100</td><td>Impact of Telemonitoring for the Management of Side Effects in Patients with Mel...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT04899921" target="_blank">NCT04899921</a></td><td>PHASE2</td><td>TERMINATED</td><td>1</td><td>A Blinded, Randomized Phase 2 Study of Troriluzole in Combination With Ipilimuma...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00796991" target="_blank">NCT00796991</a></td><td>PHASE1</td><td>COMPLETED</td><td>72</td><td>A Randomized, Parallel, 3-arm Study to Characterize the Effect of Ipilimumab + C...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01973608" target="_blank">NCT01973608</a></td><td>PHASE2</td><td>TERMINATED</td><td>12</td><td>A Safety Study for MSB0010445 in Combination With Stereotactic Body Radiation in...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT04860076" target="_blank">NCT04860076</a></td><td>N/A</td><td>UNKNOWN</td><td>400</td><td>Open-label, Uncontrolled, Non-Interventional, Retrospective Study to Evaluate Mo...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00972933" target="_blank">NCT00972933</a></td><td>EARLY_PHASE1</td><td>COMPLETED</td><td>59</td><td>Neoadjuvant Anti-CTLA4 Blockade With Ipilimumab in Patients With AJCC Stage IIIB...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT04940299" target="_blank">NCT04940299</a></td><td>PHASE2</td><td>ACTIVE_NOT_RECRUITING</td><td>35</td><td>A Phase II Study to Assess the Safety and Efficacy of Tocilizumab in Combination...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01363206" target="_blank">NCT01363206</a></td><td>PHASE2</td><td>COMPLETED</td><td>29</td><td>GM-CSF and Ipilimumab as Therapy in Metastatic Melanoma, a Phase II Study</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT04866810" target="_blank">NCT04866810</a></td><td>NA</td><td>SUSPENDED</td><td>24</td><td>The Effect of Diet and Exercise on ImmuNotherapy and the Microbiome (EDEN)</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00871481" target="_blank">NCT00871481</a></td><td>PHASE1, PHASE2</td><td>COMPLETED</td><td>10</td><td>Laboratory-Treated T Cells and Ipilimumab in Treating Patients With Metastatic M...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT06999980" target="_blank">NCT06999980</a></td><td>PHASE2</td><td>NOT_YET_RECRUITING</td><td>494</td><td>A Phase II, Multicentre, Parallel Group, Open Label, Randomised Clinical Trial o...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01323517" target="_blank">NCT01323517</a></td><td>PHASE2</td><td>COMPLETED</td><td>26</td><td>A Phase II Trial of The Addition of Ipilimumab (MDX-010) To Isolated Limb Infusi...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT06295159" target="_blank">NCT06295159</a></td><td>PHASE2</td><td>RECRUITING</td><td>90</td><td>Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Me...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01496807" target="_blank">NCT01496807</a></td><td>PHASE1</td><td>COMPLETED</td><td>31</td><td>A Phase Ib Study of Yervoy With Sylatron for Patients With Unresectable Stages I...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT03348891" target="_blank">NCT03348891</a></td><td>NA</td><td>COMPLETED</td><td>60</td><td>TNF in Melanoma Patients Treated With Immunotherapy</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT02009384" target="_blank">NCT02009384</a></td><td>PHASE2</td><td>TERMINATED</td><td>2</td><td>A Phase II Open-Label Study of Ipilimumab Administered to Stage IIIC and Stage I...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT03126110" target="_blank">NCT03126110</a></td><td>PHASE1, PHASE2</td><td>COMPLETED</td><td>145</td><td>A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN0187...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT03458455" target="_blank">NCT03458455</a></td><td>N/A</td><td>UNKNOWN</td><td>200</td><td>Improved Therapy Response Assessment in Metastatic Brain Tumors</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT05428007" target="_blank">NCT05428007</a></td><td>PHASE2</td><td>RECRUITING</td><td>105</td><td>A Phase II Study of the Interleukin-6 Receptor Inhibitor Sarilumab in Combinatio...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT04951583" target="_blank">NCT04951583</a></td><td>PHASE2</td><td>ACTIVE_NOT_RECRUITING</td><td>45</td><td>Phase II Trial of Fecal Microbial Transplantation in Patients With Advanced Non-...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT05384496" target="_blank">NCT05384496</a></td><td>PHASE2</td><td>RECRUITING</td><td>20</td><td>Phase 2 Study of Axitinib + PD-1 Blockade in Mucosal Melanoma With Pilot Additio...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT03469960" target="_blank">NCT03469960</a></td><td>PHASE3</td><td>COMPLETED</td><td>265</td><td>A Randomized Phase 3 Trial Comparing Continuation Nivolumab-Ipilimumab Doublet I...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT06116461" target="_blank">NCT06116461</a></td><td>PHASE4</td><td>RECRUITING</td><td>34</td><td>Nivolumab Dose Optimization in Patients With a Complete, Partial or Stable Respo...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00162123" target="_blank">NCT00162123</a></td><td>PHASE2</td><td>COMPLETED</td><td>248</td><td>A Multi-Center, Open-Label, Phase II Study of Ipilimumab (MDX-010 Extended-Treat...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01708941" target="_blank">NCT01708941</a></td><td>PHASE2</td><td>ACTIVE_NOT_RECRUITING</td><td>88</td><td>A Randomized Phase II Study of Ipilimumab at 3 mg/kg or 10 mg/kg Alone or in Com...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT02626962" target="_blank">NCT02626962</a></td><td>PHASE2</td><td>COMPLETED</td><td>52</td><td>Phase II Multicenter, Non Randomized, Open Label Trial of Nivolumab in Combinati...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01709162" target="_blank">NCT01709162</a></td><td>PHASE2</td><td>TERMINATED</td><td>31</td><td>A Randomized, Open-Label, Multicenter Phase II Study of Ipilimumab Retreatment V...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01844505" target="_blank">NCT01844505</a></td><td>PHASE3</td><td>COMPLETED</td><td>945</td><td>A Phase 3, Randomized, Double-Blind Study of Nivolumab Monotherapy or Nivolumab ...</td></tr>
</tbody>
</table>

<h3>ç›¸é—œæ–‡ç»ï¼ˆ5 ç¯‡ï¼‰</h3>

<table>
<thead>
<tr><th>PMID</th><th>å¹´ä»½</th><th>é¡å‹</th><th>æœŸåˆŠ</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/24999899/" target="_blank">24999899</a></td><td>2014</td><td>Article</td><td>The Medical journal of Austral</td><td>Ipilimumab in pretreated patients with unresectable or metastatic cutaneous, uve...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/28183255/" target="_blank">28183255</a></td><td>2018</td><td>Article</td><td>Current cancer drug targets</td><td>Melanoma Adjuvant Treatment: Current Insight and Clinical Features.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/29466692/" target="_blank">29466692</a></td><td>2018</td><td>Article</td><td>Discovery medicine</td><td>Anti-programmed cell death-1 (PD-1) monoclonal antibodies in treating advanced m...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/37887546/" target="_blank">37887546</a></td><td>2023</td><td>Article</td><td>Current oncology (Toronto, Ont</td><td>Effectiveness of Immune Checkpoint Inhibitor with Anti-PD-1 Monotherapy or in Co...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/40236344/" target="_blank">40236344</a></td><td>2025</td><td>Article</td><td>Cureus</td><td>A Case Report of Metastatic Melanoma in the Transverse Colon.</td></tr>
</tbody>
</table>

</div>
</details>


## å°ç£ä¸Šå¸‚è³‡è¨Š

**æœ‰æ•ˆè¨±å¯è­‰ï¼š**

| è¨±å¯è­‰å­—è™Ÿ | å•†å“å | è¨±å¯è­‰æŒæœ‰è€… | æ•ˆæœŸ |
|------------|--------|--------------|------|
| è¡›éƒ¨èŒç–«è¼¸å­—ç¬¬000958è™Ÿ | ç›Šä¼æ³¨å°„åŠ‘ 5 æ¯«å…‹/æ¯«å‡ | å°ç£å¿…æ²»å¦¥æ–½è²´å¯¶ | 2029/08/18 |

**æ ¸å‡†é©æ‡‰ç—‡ï¼ˆèˆ‡ nivolumab ä½µç”¨ï¼‰ï¼š**
1. ç„¡æ³•åˆ‡é™¤æˆ–è½‰ç§»æ€§é»‘è‰²ç´ ç˜¤ï¼ˆ12 æ­²ä»¥ä¸Šï¼‰
2. æ™šæœŸè…ç´°èƒç™Œï¼ˆä¸­åº¦/é‡åº¦é¢¨éšªï¼‰
3. MSI-H/dMMR è½‰ç§»æ€§å¤§è…¸ç›´è…¸ç™Œ
4. è‚ç´°èƒç™Œï¼ˆç¬¬ä¸€ç·šå’Œ sorafenib å¤±æ•—å¾Œï¼‰
5. è½‰ç§»æ€§æˆ–å¾©ç™¼æ€§éå°ç´°èƒè‚ºç™Œ
6. æƒ¡æ€§è‚‹è†œé–“çš®ç˜¤
7. é£Ÿé“é±—ç‹€ç´°èƒç™Œ

## å®‰å…¨æ€§è€ƒé‡

### å…ç–«ç›¸é—œä¸è‰¯äº‹ä»¶ (irAEs)

Ipilimumab + Nivolumab ä½µç”¨ç™‚æ³•çš„ Grade 3-4 irAEs ç™¼ç”Ÿç‡ç´„ 50-60%ï¼š

| ä¸è‰¯åæ‡‰é¡å‹ | å¸¸è¦‹è¡¨ç¾ | ç®¡ç†é‡é» |
|--------------|----------|----------|
| è…¸ç‚ | è…¹ç€‰ã€è¡€ä¾¿ | å¯èƒ½éœ€ corticosteroids |
| è‚ç‚ | è½‰æ°¨é…¶å‡é«˜ | ç›£æ¸¬è‚åŠŸèƒ½ |
| çš®è†šç‚ | çš®ç–¹ã€æ”ç™¢ | å¤–ç”¨/å…¨èº«æ€§ steroids |
| å…§åˆ†æ³Œç—…è®Š | ç”²ç‹€è…º/è…ä¸Šè…ºåŠŸèƒ½ç•°å¸¸ | è·çˆ¾è’™è£œå…… |
| è‚ºç‚ | å‘¼å¸å›°é›£ã€å’³å—½ | åœè—¥ä¸¦çµ¦äºˆ steroids |
| è…¸ç©¿å­” | ç½•è¦‹ä½†è‡´å‘½ | ç·Šæ€¥å¤–ç§‘ä»‹å…¥ |

### ä¸»è¦è—¥ç‰©äº¤äº’ä½œç”¨

| äº¤äº’ä½œç”¨è—¥ç‰© | åš´é‡ç¨‹åº¦ | èªªæ˜ |
|--------------|----------|------|
| Corticosteroids | Moderate | å¯èƒ½é™ä½å…ç–«æ²»ç™‚æ•ˆæœ |
| Hydrocortisone | Moderate | ç”¨æ–¼ irAEs ç®¡ç†æ™‚éœ€æ¬Šè¡¡ |
| Dexamethasone | Moderate | åŒä¸Š |
| å…¶ä»–å…ç–«æŠ‘åˆ¶åŠ‘ | Moderate | å¯èƒ½å½±éŸ¿ç™‚æ•ˆ |

### ç‰¹æ®Šæ—ç¾¤
- **è‚åŠŸèƒ½ä¸å…¨**ï¼šè¼•åº¦è‚åŠŸèƒ½ä¸å…¨ä¸éœ€èª¿æ•´åŠ‘é‡
- **è…åŠŸèƒ½ä¸å…¨**ï¼šä¸éœ€èª¿æ•´åŠ‘é‡
- **å­•å©¦**ï¼šç¦ç”¨ï¼Œå¯èƒ½è‡´ç•¸
- **è€å¹´æ‚£è€…**ï¼šæ¯’æ€§å¯èƒ½å¢åŠ ï¼Œéœ€å¯†åˆ‡ç›£æ¸¬


### è—¥ç‰©-ç–¾ç—…æ³¨æ„äº‹é … (DDSI)

<div class="ddsi-source">è³‡æ–™ä¾†æºï¼š<a href="https://ddinter2.scbdd.com/" target="_blank">DDInter 2.0</a>ï¼ˆåŸæ–‡å…§å®¹è«‹åƒé–±è©²ç¶²ç«™ï¼‰</div>

**Hepatic Insufficiency** ğŸŸ¡ Moderate
- å¯èƒ½æœ‰åš´é‡ä¸è‰¯åæ‡‰ã€‚

**Pneumonia** ğŸŸ¡ Moderate
- å¿…è¦æ™‚æ‡‰åœæ­¢æ²»ç™‚ã€‚

**Colitis** ğŸŸ¢ Minor
- é¢¨éšªåŒ…æ‹¬ï¼šæ„ŸæŸ“ã€‚å¯èƒ½æœ‰è‡´å‘½é¢¨éšªã€‚å¿…è¦æ™‚æ‡‰åœæ­¢æ²»ç™‚ã€‚

**Dermatitis** ğŸŸ¢ Minor
- å‡ºç¾ç—‡ç‹€æ™‚æ‡‰è€ƒæ…®åœè—¥ã€‚

**Endocrine System Diseases** ğŸŸ¢ Minor
- éœ€å®šæœŸç›£æ¸¬ã€‚å¯èƒ½å±åŠç”Ÿå‘½ã€‚å‡ºç¾ç—‡ç‹€æ™‚æ‡‰è€ƒæ…®åœè—¥ã€‚

**Hepatitis** ğŸŸ¢ Minor
- éœ€å®šæœŸç›£æ¸¬ã€‚å¯èƒ½æœ‰è‡´å‘½é¢¨éšªã€‚å‡ºç¾ç—‡ç‹€æ™‚æ‡‰è€ƒæ…®åœè—¥ã€‚

**Graft vs Host Disease** ğŸŸ¢ Minor
- éœ€å¯†åˆ‡ç›£æ¸¬ã€‚å¯èƒ½æœ‰è‡´å‘½é¢¨éšªã€‚

**Immune System Diseases** ğŸŸ¢ Minor
- éœ€å®šæœŸç›£æ¸¬ã€‚å¯èƒ½æœ‰è‡´å‘½é¢¨éšªã€‚å‡ºç¾ç—‡ç‹€æ™‚æ‡‰è€ƒæ…®åœè—¥ã€‚

**Eye Diseases** ğŸŸ¢ Minor
- éœ€å®šæœŸç›£æ¸¬ã€‚å¯èƒ½æœ‰è‡´å‘½é¢¨éšªã€‚å‡ºç¾ç—‡ç‹€æ™‚æ‡‰è€ƒæ…®åœè—¥ã€‚

## çµè«–èˆ‡ä¸‹ä¸€æ­¥

### é æ¸¬è©•ä¼°çµè«–

Ipilimumab å°éçš®è†šé»‘è‰²ç´ ç˜¤çš„é æ¸¬æ˜¯**é«˜åº¦æœ‰åƒ¹å€¼çš„ç™¼ç¾**ï¼š

1. **è‘¡è„è†œé»‘è‰²ç´ ç˜¤**ï¼šå·²æœ‰ Phase 2 è©¦é©—æ•¸æ“šï¼Œé¡¯ç¤ºèˆ‡ nivolumab ä½µç”¨çš„ç™‚æ•ˆ
2. **é»è†œé»‘è‰²ç´ ç˜¤**ï¼šå¤šé …é€²è¡Œä¸­çš„è‡¨åºŠè©¦é©—æ­£åœ¨è©•ä¼°
3. **è„ˆçµ¡è†œç„¡è™¹è†œç—‡**ï¼šæ­¤é æ¸¬ç¼ºä¹æ©Ÿè½‰æ”¯æŒï¼Œå¯èƒ½ç‚ºå½é™½æ€§

### è­‰æ“šç­‰ç´šç¸½çµ

| é æ¸¬é©æ‡‰ç—‡ | TxGNN Score | è­‰æ“šç­‰ç´š | è©•ä¼° |
|------------|-------------|----------|------|
| éçš®è†šé»‘è‰²ç´ ç˜¤ | 0.990 | **L1/L2** | å¤šé … RCT æ”¯æŒï¼Œæ¥µé«˜åƒ¹å€¼ |
| è„ˆçµ¡è†œç„¡è™¹è†œç—‡ | 0.991 | L5 | æ©Ÿè½‰ä¸æ˜ï¼Œå¯èƒ½å½é™½æ€§ |

### å»ºè­°

1. **éçš®è†šé»‘è‰²ç´ ç˜¤**ï¼š
   - **å¼·çƒˆå»ºè­°æŒçºŒè¿½è¹¤è‡¨åºŠè©¦é©—é€²å±•**
   - ç¾æœ‰ Phase 2 è©¦é©—ï¼ˆNCT02626962ï¼‰çµæœå·²ç™¼è¡¨
   - å¯ä½œç‚ºè‡¨åºŠæ±ºç­–åƒè€ƒ
   - éƒ¨åˆ†äºå‹å¯èƒ½å·²å¯åœ¨ä»¿å–®å¤–ä½¿ç”¨æ¢ä»¶ä¸‹æ‡‰ç”¨

2. **é©æ‡‰ç—‡æ“´å¢å»ºè­°**ï¼š
   - è‘¡è„è†œé»‘è‰²ç´ ç˜¤å’Œé»è†œé»‘è‰²ç´ ç˜¤çš„è­‰æ“šå·²ç›¸å°æˆç†Ÿ
   - å¯è€ƒæ…®å‘ TFDA æäº¤é©æ‡‰ç—‡æ“´å¢ç”³è«‹

3. **è‡¨åºŠæ‡‰ç”¨æ³¨æ„äº‹é …**ï¼š
   - éçš®è†šé»‘è‰²ç´ ç˜¤é å¾Œé€šå¸¸è¼ƒçš®è†šå‹å·®
   - éœ€è¬¹æ…è©•ä¼°ç—…æ‚£ç‹€æ³å’Œ irAEs é¢¨éšª
   - å»ºè­°åœ¨æœ‰å…ç–«æ²»ç™‚ç¶“é©—çš„ä¸­å¿ƒä½¿ç”¨

---

*å ±å‘Šç”Ÿæˆæ—¥æœŸï¼š2026-02-11*
*è³‡æ–™ä¾†æºï¼šTxGNN çŸ¥è­˜åœ–è­œé æ¸¬ã€ClinicalTrials.govã€PubMedã€å°ç£ FDA*

---

## ç›¸é—œè—¥ç‰©å ±å‘Š

- [Buprenorphine]({{ "/drugs/buprenorphine/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Famotidine]({{ "/drugs/famotidine/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Loteprednol Etabonate]({{ "/drugs/loteprednol_etabonate/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Ouabain]({{ "/drugs/ouabain/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Aspirin]({{ "/drugs/aspirin/" | relative_url }}) - è­‰æ“šç­‰ç´š L5

---

{% include ai-analysis.html %}

{% include social-share.html %}

## å¼•ç”¨æœ¬å ±å‘Š

å¦‚éœ€å¼•ç”¨æœ¬å ±å‘Šï¼Œè«‹ä½¿ç”¨ä»¥ä¸‹æ ¼å¼ï¼š

**APA æ ¼å¼ï¼š**
```
TwTxGNN. (2026). Ipilimumabè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š. https://twtxgnn.yao.care/drugs/ipilimumab/
```

**BibTeX æ ¼å¼ï¼š**
```bibtex
@misc{twtxgnn_ipilimumab,
  title = {Ipilimumabè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š},
  author = {TwTxGNN Team},
  year = {2026},
  url = {https://twtxgnn.yao.care/drugs/ipilimumab/}
}
```

---

<div class="disclaimer">
<strong>å…è²¬è²æ˜</strong><br>
æœ¬å ±å‘Šåƒ…ä¾›å­¸è¡“ç ”ç©¶åƒè€ƒï¼Œ<strong>ä¸æ§‹æˆé†«ç™‚å»ºè­°</strong>ã€‚è—¥ç‰©ä½¿ç”¨è«‹éµå¾ªé†«å¸«æŒ‡ç¤ºï¼Œåˆ‡å‹¿è‡ªè¡Œèª¿æ•´ç”¨è—¥ã€‚ä»»ä½•è€è—¥æ–°ç”¨æ±ºç­–éœ€ç¶“éå®Œæ•´çš„è‡¨åºŠé©—è­‰èˆ‡æ³•è¦å¯©æŸ¥ã€‚
<br><br>
<small>æœ€å¾Œå¯©æ ¸ï¼š2026-02-20 | å¯©æ ¸è€…ï¼šTwTxGNN Research Team</small>
</div>

{% include giscus.html %}
